$3.90
9.24%
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US15117K1034
Symbol
CLLS

Cellectis SA Sponsored ADR Stock price

$3.90
-0.27 6.47% 1M
+2.52 182.61% 6M
+2.10 116.67% YTD
+1.99 104.19% 1Y
+1.60 69.57% 3Y
-16.16 80.56% 5Y
-30.65 88.71% 10Y
-35.40 90.08% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+0.33 9.24%
ISIN
US15117K1034
Symbol
CLLS
Industry

Key metrics

Basic
Market capitalization
$269.0m
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.4 | 6.2
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
34.2%
Return on Equity
-28.1%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$112.6m | $43.3m
EBITDA
- | $-87.7m
EBIT
$-51.4m | $-89.8m
Net Income
$-76.5m | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
154.9% | -12.1%
EBITDA
- | -120.9%
EBIT
57.4% | -50.8%
Net Income
21.4% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -202.5%
EBIT
-45.6%
Net
-68.0% | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
-
Short interest
0.6%
Employees
219
Rev per Employee
$220.0k
Show more

Is Cellectis SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Cellectis SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Cellectis SA Sponsored ADR forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Cellectis SA Sponsored ADR forecast:

Buy
85%
Hold
15%

Financial data from Cellectis SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
113 113
155% 155%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
26% 26%
13%
- Research and Development Expense 65 65
0% 0%
58%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -51 -51
57% 57%
-46%
Net Profit -77 -77
21% 21%
-68%

In millions USD.

Don't miss a Thing! We will send you all news about Cellectis SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cellectis SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
9 days ago
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi First interim analysis for the BALLI-01 trial ex...
Neutral
GlobeNewsWire
14 days ago
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the acceptance of two abstracts for poster presentation at the American Society of Hematology (ASH) 2025 annual meeting taking place from De...
Neutral
GlobeNewsWire
16 days ago
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the...
More Cellectis SA Sponsored ADR News

Company Profile

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Head office France
CEO André Choulika
Employees 219
Founded 1999
Website www.cellectis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today